论文部分内容阅读
基因技术公司宣布双特异性单克隆抗体依米珠单抗(emicizumab)治疗A型血友病的Ⅲ期临床试验中期结果。Ⅲ期临床HAVEN 1试验是随机、多中心、开放的研究,入选109名>12岁的A型血友病患者,评价该药预防出血的疗效、安全性和药代动力学,与不用该药预防而用因子Ⅷ抑制剂组的比较。主终点是该药预
Gene Technologies Inc. announced the interim results of Phase III clinical trial of bispecific monoclonal antibody emicizumab in the treatment of hemophilia A. The Phase III HAVEN 1 trial was a randomized, multicenter, open-ended study of 109 patients aged> 12 years with type A hemophilia who evaluated the efficacy, safety and pharmacokinetics of the drug in preventing bleeding, Prevention vs Factor VIII inhibitor group. The main endpoint is the drug pre-